Gilead Sciences Inc. reported third-quarter results largely in line with Wall Street estimates, led by higher sales of the company’s HIV drugs, but deal-related costs led to a net loss.
Researchers at the National Institutes of Health (NIH) and Massachusetts General Hospital (MGH) in Boston published research that found an injectable hormone called tesamorelin decreases liver fat and prevented liver fibrosis in HIV patients affected by non-alcoholic fatty liver disease.
Researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key switch that has the potential to eliminate dormant HIV reservoirs.
W2O – the leading independent analytics-driven, digital-first marketing communications firm to the healthcare sector – will provide regional communications support to the International AIDS Society (IAS) for AIDS 2020, the 23rd International AIDS Conference.
The U.S. FDA approved Merck’s supplemental New Drug Applications for Pifeltro (in combination with other antiretroviral agents) and Delstrigo (as a complete regimen) that expand their indications to include adult patients with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to Pifeltro or the individual components of Delstrigo.
GlaxoSmithKline’s experimental HIV injection is as effective when given every other month as monthly, according to a study
An FDA advisory panel voted in favor of Gilead’s combination drug to reduce the risk of sexually acquired HIV infection in men.
Gilead Sciences Inc. beat Wall Street estimates for second-quarter 2019 revenue and profit, driven by higher sales of HIV treatments, and the U.S. drugmaker raised the company’s full-year sales forecast.
GlaxoSmithKline, Pfizer and Shinogi’s joint venture ViiV Healthcare said the Phase III BRIGHTE study hit 96-week endpoints in heavily treatment-experienced adults with HIV-1 infection.
A collaboration and license deal was inked with Gilead Sciences Inc. to develop and market a long-acting injectable HIV therapy using Durect Corp.’s SABER technology.